Literature DB >> 31130416

Delusions in Alzheimer Disease are Associated With Decreased Default Mode Network Functional Connectivity.

Winnie Qian1, Corinne E Fischer2, Nathan W Churchill3, Sanjeev Kumar4, Tarek Rajji5, Tom A Schweizer6.   

Abstract

OBJECTIVE: Approximately one-third of patients with Alzheimer disease (AD) develop delusions. Delusions have been linked to numerous adverse outcomes, including worsened cognitive and functional decline, increased caregiver burden, and higher mortality rates. Previous studies have indicated that both AD and neuropsychiatric symptoms within AD are associated with abnormal functional connectivity of the resting brain, but no studies have focused on how delusions alter resting-state functional connectivity. The authors' objective was to test for differences in resting brain function between delusional and non-delusional patients with AD. The authors hypothesized that patients with AD with delusions would exhibit reduced connectivity of the default mode network (DMN) compared with patients with AD without delusions.
METHODS: Resting-state functional magnetic resonance imaging was used to investigate differences in functional connectivity between 15 patients with AD with delusions and 15 comparable patients with AD without delusions. A group-level principal component analysis was used to identify functional networks accounting for greatest variability over all subjects, and the DMN was selected for between-group analysis. Dual regression was used to reconstruct individual subject component maps, and a two-sample t test was used to compare groups with and without delusion, adjusted at a false discovery rate of 0.05.
RESULTS: The two cohorts were comparable demographically and cognitively. The patients with delusions showed significantly reduced connectivity of the left inferior parietal lobule (IPL) with the rest of the DMN.
CONCLUSION: Delusions in AD are associated with reduced connectivity within the DMN, specifically the left IPL. The authors' findings provide insight into the underlying neuropathophysiology of delusions in AD.
Copyright © 2019 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; delusions; imaging; resting-state

Year:  2019        PMID: 31130416     DOI: 10.1016/j.jagp.2019.03.020

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  5 in total

1.  The neural signatures of psychoses in Alzheimer's disease: a neuroimaging genetics approach.

Authors:  Riccardo Manca; Antonio F Pardiñas; Annalena Venneri
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-06-21       Impact factor: 5.270

2.  Accelerated atrophy in dopaminergic targets and medial temporo-parietal regions precedes the onset of delusions in patients with Alzheimer's disease.

Authors:  Riccardo Manca; Jose Manuel Valera-Bermejo; Annalena Venneri
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-13       Impact factor: 5.270

Review 3.  Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities.

Authors:  Zahinoor Ismail; Byron Creese; Dag Aarsland; Helen C Kales; Constantine G Lyketsos; Robert A Sweet; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2022-01-04       Impact factor: 44.711

4.  Alterations of regional homogeneity in Parkinson's disease with mild cognitive impairment: a preliminary resting-state fMRI study.

Authors:  Ming-Ge Li; Tie-Fang Liu; Tian-Hao Zhang; Zhi-Ye Chen; Bin-Bin Nie; Xin Lou; Zhen-Fu Wang; Lin Ma
Journal:  Neuroradiology       Date:  2019-12-10       Impact factor: 2.804

5.  Elamipretide (SS-31) Improves Functional Connectivity in Hippocampus and Other Related Regions Following Prolonged Neuroinflammation Induced by Lipopolysaccharide in Aged Rats.

Authors:  Yang Liu; Huiqun Fu; Yan Wu; Binbin Nie; Fangyan Liu; Tianlong Wang; Wei Xiao; Shuyi Yang; Minhui Kan; Long Fan
Journal:  Front Aging Neurosci       Date:  2021-03-01       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.